Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...
After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...
La voie semble désormais libre pour le rachat par Pfizer de la biotech américaine Metsera, spécialiste des traitements ...
San Francisco — La voie semble désormais libre pour le rachat par Pfizer de la biotech américaine Metsera, spécialiste des ...
Pfizer Inc. (NYSE:PFE) is one of the best value stocks in Goldman Sachs’ portfolio. The company appears to have seized an opportunity that may help it strengthen its portfolio with newer therapies in ...
BFM Business on MSN
Novo Nordisk jette l'éponge, Pfizer a le champ libre
Pfizer s'apprête à acquérir Metsera, spécialiste des traitements anti-obésité, après l'acceptation d'une offre relevée. Novo ...
With a market cap of $144.8 billion, New York-based Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, and markets innovative medicines and vaccines across diverse ...
We recently published 11 Stocks Crushing Wall Street With Whopping Gains. Pfizer Inc. (NYSE:PFE) is one of the top performers on Tuesday. Pfizer Inc. extended its winning streak to a third straight ...
Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Paying Stocks to Buy Now. Pfizer Inc. (NYSE:PFE) ranks among the world’s top pharmaceutical companies, with vast resources to back its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback